Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ENOVID vs ADQUEY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination estrogen-progestin contraceptive; suppresses gonadotropins (LH, FSH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining to impair implantation.
ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.
Oral contraception,Treatment of endometriosis,Dysfunctional uterine bleeding,Postponement of menstruation
Alzheimer disease (FDA approved for treatment of mild cognitive impairment or mild dementia stage),Off-label: none established
Oral, 5 mg daily for 20 days starting on day 5 of menstrual cycle for ovulation inhibition; for endometriosis, 5 mg daily for 15 days increasing to 10 mg daily if breakthrough bleeding occurs.
400 mg orally once daily with food.
Norethynodrel: 5-12 hours; mestranol: 7-20 hours. Terminal half-life of ethinyl estradiol from mestranol conversion: 10-30 hours. Clinical context: steady-state achieved after 3-5 half-lives (3-5 days).
Terminal half-life 12-15 hours; prolonged in renal impairment (up to 30 hours in Cr Cl <30 m L/min)
Hepatic via CYP3A4; norethynodrel is metabolized to norethindrone; mestranol is demethylated to ethinyl estradiol; metabolites undergo glucuronidation and sulfation.
Metabolized via catabolic pathways similar to endogenous Ig G; no specific cytochrome P450 enzyme involvement.
Renal (30-50% as metabolites, <5% unchanged) and fecal (40-60% via bile, mostly as glucuronide conjugates).
Renal: 70-80% unchanged; Fecal: 5-10% as metabolites; Biliary: minimal (<2%)
Norethynodrel: 95-97% bound to albumin; mestranol: >95% bound to albumin and sex hormone-binding globulin (SHBG).
98% bound to albumin
Norethynodrel: ~2.0 L/kg; mestranol: ~3.5 L/kg. High Vd indicates extensive tissue distribution.
0.2-0.3 L/kg; indicates limited extravascular distribution
Oral: 80-100% for norethynodrel; mestranol: 40-60% (first-pass metabolism to ethinyl estradiol).
Oral: 85-90%; IM: 95-100%
No specific dose adjustment guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential fluid retention.
Cr Cl ≥60 m L/min: no adjustment; Cr Cl 30-59 m L/min: 200 mg daily; Cr Cl <30 m L/min: 100 mg daily; hemodialysis: 100 mg daily after dialysis.
Contraindicated in severe hepatic impairment (Child-Pugh C); in mild to moderate impairment (Child-Pugh A or B), reduce dose by 50% or use alternative therapy.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg daily; Child-Pugh C: not recommended.
Not recommended for use in pediatric patients for contraception; for endometriosis in adolescents, dose same as adult adjusted for weight (0.1-0.2 mg/kg/day norethynodrel equivalent, max 5 mg/day).
Weight ≥10 kg: 12 mg/kg/dose twice daily; weight <10 kg: 8 mg/kg/dose twice daily.
Not indicated for contraception in postmenopausal women; if used for other indications, monitor for thromboembolic events and electrolyte disturbances; initiate at lowest effective dose (2.5 mg/day).
Initial dose 200 mg daily; titrate based on renal function; monitor for neuropsychiatric effects.
Cigarette smoking increases risk of serious cardiovascular events; contraindicated in women over 35 who smoke.
Amyloid-related imaging abnormalities (ARIA), including ARIA-E (edema/effusion) and ARIA-H (hemosiderin deposition), can occur. ARIA is usually asymptomatic but serious events including seizure and status epilepticus have been reported. Patients with apolipoprotein E ε4 homozygosity have a higher incidence of ARIA.
Increased risk of thromboembolic disorders (stroke, MI, DVT, PE), hepatic neoplasia, gallbladder disease, hypertension, glucose intolerance, and depression. Discontinue if jaundice or visual disturbances occur.
1) Amyloid-related imaging abnormalities (ARIA): monitor with MRI before and during treatment; consider dose interruption or discontinuation if severe. 2) Hypersensitivity reactions: angioedema, urticaria reported. 3) Risk of falls due to cognitive impairment. 4) No head-to-head trials showing superiority over other treatments.
Thrombophlebitis or thromboembolic disorders, cerebrovascular or coronary artery disease, known or suspected breast carcinoma, undiagnosed abnormal genital bleeding, pregnancy, known or suspected estrogen-dependent neoplasia, impaired liver function, history of cholestatic jaundice of pregnancy, heavy smoking (>15 cigarettes/day) in women over 35.
History of severe hypersensitivity to aducanumab or any excipients in ADQUEY.
No significant food interactions. Grapefruit juice may increase estrogen levels; avoid large amounts. Maintain consistent dietary habits to avoid fluctuations in hormone levels.
Avoid grapefruit and grapefruit juice; may increase drug levels. High-fat meals can increase absorption; take with food or on an empty stomach consistently.
First trimester: Risk of fetal cardiovascular defects, neural tube defects, and cleft lip/palate. Second and third trimesters: Possible feminization of male fetuses (hypospadias) and clitoral enlargement in females. Postnatal: Vaginal adenosis and clear cell adenocarcinoma of the vagina/cervix in females exposed in utero.
ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Second and third trimester exposure may lead to feminization of male fetuses and other adverse outcomes.
Excretion into breast milk occurs; M/P ratio not established. Avoid use during breastfeeding due to potential hormonal effects on infant. Alternative contraception recommended.
Excretion into breast milk is minimal; however, ADQUEY may reduce milk production and quality. M/P ratio not established. Avoid use during breastfeeding.
Contraindicated in pregnancy. No dosing adjustments applicable; if inadvertent exposure occurs, immediately discontinue the drug and provide counseling regarding risks.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue immediately if pregnancy occurs.
Monitor for thromboembolic events, especially in women over 35 who smoke. Use lowest effective dose for shortest duration. Discontinue 4 weeks before elective surgery to reduce clotting risk. Not recommended for contraception due to high estrogen dose.
Administration with a full glass of water and staying upright for 30 minutes reduces risk of esophagitis. Monitor for cutaneous lupus erythematosus and Stevens-Johnson syndrome. Avoid concomitant use with drugs that prolong QT interval due to risk of torsades de pointes.
Take at same time daily with food to reduce nausea.,Report symptoms of blood clots: chest pain, sudden shortness of breath, leg pain/swelling, severe headache, vision changes.,Do not use if pregnant or breastfeeding; seek alternative contraception.,Smoking increases risk of serious cardiovascular side effects.,Use backup contraception if vomiting occurs within 4 hours of dose.
Take exactly as prescribed; do not double doses if missed.,Swallow tablet whole; do not crush or chew.,Avoid direct sunlight; use sunscreen and protective clothing.,Report any skin rash, blisters, or eye irritation immediately.,Do not take with antacids, iron supplements, or sucralfate; separate by at least 4 hours.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ENOVID vs ADQUEY, answered by our medical review team.
ENOVID is a Oral Contraceptive that works by Combination estrogen-progestin contraceptive; suppresses gonadotropins (LH, FSH) via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases viscosity of cervical mucus and alters endometrial lining to impair implantation.. ADQUEY is a Oral Contraceptive that works by ADQUEY (aducanumab) is a human monoclonal antibody that selectively targets aggregated forms of amyloid beta (Aβ), including soluble oligomers and insoluble fibrils, reducing Aβ plaques in the brain. The exact mechanism linking Aβ reduction to clinical improvement is not fully established.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ENOVID and ADQUEY depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ENOVID is: Oral, 5 mg daily for 20 days starting on day 5 of menstrual cycle for ovulation inhibition; for endometriosis, 5 mg daily for 15 days increasing to 10 mg daily if breakthrough bleeding occurs.. The standard adult dose of ADQUEY is: 400 mg orally once daily with food.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ENOVID and ADQUEY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ENOVID is classified as Category C. First trimester: Risk of fetal cardiovascular defects, neural tube defects, and cleft lip/palate. Second and third trimesters: Possible feminization of male fetuses (hypospadias) a. ADQUEY is classified as Category C. ADQUEY (estradiol valerate/dienogest) is contraindicated in pregnancy. First trimester exposure may cause congenital anomalies including cardiovascular and neural tube defects. Sec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.